Tabetha Maslow
Family · Grapevine, TXNPI 1700255684
Payments from drug & device makers
Across 93 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$321
- AbbVie$271
- Pfizer$167
- GSK$162
- Novo Nordisk$137
- AstraZeneca$81
- plus $491 from 14 others
What the payments were for
- Food & beverage$1,631100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $321 |
| AbbVie | 18 | $271 |
| Pfizer | 9 | $167 |
| GSK | 10 | $162 |
| Novo Nordisk | 8 | $137 |
| AstraZeneca | 4 | $81 |
| Johnson & Johnson | 5 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Amgen | 3 | $53 |
| Antares Pharma, Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $47 |
| Eisai Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Exact Sciences | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $22 |
| Clarus Therapeutics Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Merck | 1 | $16 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$100
How this compares
$1,631 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $45,961 |
| FarxigaDapagliflozin Propanediol | 20 | $20,168 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $1,322 |
| Liothyronine Sodium | 24 | $845 |
| Levothyroxine Sodium | 101 | $817 |
| ProgesteroneProgesterone, Micronized | 19 | $723 |
| SynthroidLevothyroxine Sodium | 13 | $720 |
| Montelukast Sodium | 33 | $682 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 14 | $679 |
| Gabapentin | 28 | $616 |
| Rosuvastatin Calcium | 53 | $611 |
| Omeprazole | 37 | $557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $550 |
| Lisinopril | 49 | $515 |
| Atorvastatin Calcium | 55 | $512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $137 | $45,96128 claims |
| AstraZenecaFarxiga | $81 | $20,16820 claims |
| AbbVieSynthroid | $271 | $72013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Grapevine
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.